ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in ...
Rusfertide maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks in the VERIFY study. Patients switching from placebo to rusfertide showed rapid ...
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., December 06, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from ...
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data ...
Patients with polycythemia vera (PV) taking the investigational therapy rusfertide were able to largely maintain hematocrit control and avoid the need for phlebotomy over 52 weeks, according to ...
Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer ...
Every year, millions of newborns — especially those born premature, underweight or sick — are at risk of neonatal ...
The world’s supply of many life-saving medications depends on people in the United States deciding to sell their blood plasma ...
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback